Quantitative determination of cyanoacetic acid content in teriflunomide drug substance by ion chromatography using conductivity detector

[1] Miller AE(2017)Teriflunomide in multiple sclerosis: an update Neurodegener Dis Manag 7 9-29

[2] Magne D(2006)The active metabolite of leflunomide, A77 1726, increases proliferation of human synovial fibroblasts in presence of IL-1beta and TNF-alpha Inflammation Research. 55 469-475

[3] Mézin F(2010)Emerging therapies in relapsing-remitting multiple sclerosis Rev Recent Clin Trials 5 179-188

[4] Palmer G(1998)Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide Biochem J 336 299-303

[5] Guerne PA(2006)A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses Neurology 66 894-900

[6] Marriott JJ(2009)Monoclonal antibodies in multiple sclerosis treatment: current and future steps Ther Adv Neurol Disord 2 195-203

[7] O'Connor PW(2010)A rapid and simple high-performance liquid chromatography assay for the leflunomide metabolite, teriflunomide (A77 1726), in renal transplant recipients Am J Clin Pathol 133 454-457

[8] Bruneau JM(2003)Simultaneous determination of leflunomide and its active metabolite, A77 1726, in human plasma by high-performance liquid chromatography Biomed Chromatogr 17 276-281

[9] Spinella Jaegle S(2017)Quality-by-design-based development and validation of a stability-indicating UPLC method for quantification of teriflunomide in the presence of degradation products and its application to in vitro dissolution J Liq Chromatogr Relat Technol 40 517-527

[10] Fudali C(2017)Development and validation of stability indicating RP-HPLC method for estimation of teriflunomide in an active pharmaceutical ingredient J Pharm Innov 6 440-449

[1] Miller AE(2017)Teriflunomide in multiple sclerosis: an update Neurodegener Dis Manag 7 9-29

[2] Magne D(2006)The active metabolite of leflunomide, A77 1726, increases proliferation of human synovial fibroblasts in presence of IL-1beta and TNF-alpha Inflammation Research. 55 469-475

[3] Mézin F(2010)Emerging therapies in relapsing-remitting multiple sclerosis Rev Recent Clin Trials 5 179-188

[4] Palmer G(1998)Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide Biochem J 336 299-303

[5] Guerne PA(2006)A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses Neurology 66 894-900

[6] Marriott JJ(2009)Monoclonal antibodies in multiple sclerosis treatment: current and future steps Ther Adv Neurol Disord 2 195-203

[7] O'Connor PW(2010)A rapid and simple high-performance liquid chromatography assay for the leflunomide metabolite, teriflunomide (A77 1726), in renal transplant recipients Am J Clin Pathol 133 454-457

[8] Bruneau JM(2003)Simultaneous determination of leflunomide and its active metabolite, A77 1726, in human plasma by high-performance liquid chromatography Biomed Chromatogr 17 276-281

[9] Spinella Jaegle S(2017)Quality-by-design-based development and validation of a stability-indicating UPLC method for quantification of teriflunomide in the presence of degradation products and its application to in vitro dissolution J Liq Chromatogr Relat Technol 40 517-527

[10] Fudali C(2017)Development and validation of stability indicating RP-HPLC method for estimation of teriflunomide in an active pharmaceutical ingredient J Pharm Innov 6 440-449